FOSL2 and systemic sclerosis: From a preclinical perspective, Huang et al. studied the effects of nintedanib in a fos-related antigen-2 (Fra2) mouse model to determine its influence on pulmonary arterial hypertension, which is considered another significant SSc complication [22].